A gradual shift in focus from sourcing assets from overseas for application in China to bringing China-made treatments to the world is challenging the notion of what constitutes a local biotech start-up
WuXi Biologics, China’s leading provider of outsourced drug development services, doesn’t want to be constrained by borders. The company has seen a gradual international-to-domestic shift in its customer...
The Riverside Group has bought Australian injury management and occupational rehabilitation services provider Nabenet as part of a workplace wellbeing rollup strategy.
Dreame, a Beijing-headquartered vacuum cleaner maker backed by smart phone and consumer electronics giant Xiaomi, has raised RMB3.6 billion ($563 million) in Series C funding.
Primavera Capital Group has invested $600 million in two subsidiaries of Envision Group, a China-based manufacturer of wind turbines, smart batteries, and renewable energy management systems.
India’s Axis Bank has launched a distress buyout fund targeting INR35 billion ($468 million) via its asset management business.